With the bewildering drop in price after a decent trial result, I have just re-entered (after selling out of LCT a few years ago)
I am still reading up on the company, so please excuse my questions:
The recent quarterly advises "rapid advancement" of AI-168 assesments this quarter, but does anyone have a feel on when this round of studies will conclude?
Also, what are everyone's thoughts about the IP security of combining a repurposed drug with CBD? Ie. Even with patents in place, what is to stop doctors from prescribing the old drug off label plus CBD gummies rather than AI-168?
Thanks
Ann: Positive results from AI-116 in vitro studies, page-12
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 400000 | 1 |
View Market Depth
| Last trade - 09.56am 12/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |
Day chart unavailable